Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional) (352661)

From US Department of Health & Human Services: National Institutes of Health (NIH)

The National Institutes of Health (NIH), a part of the U.S. Department of Health and Human Services, is the nation’s medical research agency — making important discoveries that improve health and save lives.

Type of Support

Overview

The broad goal of the grant program is to accelerate the development of Digital Therapeutics (DTx) aimed at treating Substance Use Disorders (SUDs). This includes leveraging advances in technology to create mobile, web, or other software-based platforms capable of delivering treatments that are both safe and effective for SUD. One key objective is to advance DTx towards FDA authorization, thereby increasing the availability of effective treatments for patients with SUDs. This includes pre-clinical and/or clinical development and testing of new or existing DTx, even those initially developed for other indications.

Eligibility

Organization's Location
Global
Program Location
Global
Organization Type
up to 2.5M

Submission

Visit Apply for more information.

Similar grants